On February 7, early trading saw a 1% decrease in the price of Biocon’s shares. The United States Food and Drug Administration (USFDA) has tentatively approved the company’s abbreviated new drug application (ANDA) for dasatinib tablets.
Biocon was trading on the BSE at ₹295.15 at 9:29 a.m., down ₹3.60, or 1.21%.
This medication is approved for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia. Adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who have not responded well to previous treatments can also be treated with it.
To record the unaudited standalone and consolidated financial statements for the quarter and nine months ended December 31, 2023, the company’s board will convene on February 8.
On February 6, 2024, the share reached a 52-week high of ₹307, and on March 21, 2023, it reached a 52-week low of ₹191.60. It is currently trading 54.04% above its 52-week low and 3.86% below its 52-week high.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
